Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Preexisting Autoimmune Disease: A Nationwide Multicenter Cohort Study.
We read with great interest the article by Tison et al profiling safety and efficacy of immune checkpoint inhibitors (ICIs) in individuals with cancer and preexisting autoimmune disease (PAD) (1). In this nationwide multicenter cohort study including largest population after Kehl KL's report (2), the occurrence of the PAD flare/other immune related adverse events (irAE) was frequent but mostly manageable without ICIs discontinuation. However, some issues should be addressed. Firstly, previous studies based on relatively small sample size indicated there are differences of flare rate among PAD of different systems (Rheumatologic, Dermatologic, Endocrine, Neurologic etc.) and Rheumatologic disorder seems to be more likely to be flare (14/27; 52%) (3).